Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762303 | 0.85 | NPSR1 (0.57) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL2762588 | 0.84 | KDM1A (0.87) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL8355143 | 0.83 | MEN1 (0.84) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL2762721 | 0.81 | KDM1A (0.55) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL14090383 | 0.80 | MEN1 (0.75) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL2763179 | 0.79 | KDM1A (0.53) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL16798757 | 0.79 | KDM1A (0.82) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL2763006 | 0.79 | KDM1A (0.61) | KDM1AMEN1KMT2AMAOAPOLB | |
| SCHEMBL13109403 | 0.78 | KDM1A (0.76) | KDM1AMEN1KMT2ANPSR1MAOA | |
| SCHEMBL2763474 | 0.78 | KDM1A (0.79) | KDM1AMEN1KMT2ANPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283832-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-10-20 | — | — | EP | claimed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | claimed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | claimed |
| EP-1283832-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | disclosed |
| WO-2004112783-A1 | NEW USE IV | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | KDM1A 1332/4885MEN1 819/4885KMT2A 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.